Stocks Turn Mixed After an Early Rally

US equities closed lower today, reversing early gains, driven by mixed economic data and significant corporate specific news. While weak jobless claims and dovish Fed commentary increased September rate cut odds to 92%, and the Bank of England cut its rate by 25 bps, market sentiment was pressured by steep declines in Eli Lilly (-14%) on drug trial data and Caterpillar (-3%) following a downgrade linked to lingering tariff impacts. President Trump's new tariff announcements, including a 100% tariff on semiconductor imports with US production exemptions, created sector-specific volatility, boosting chip stocks but adding broader trade policy uncertainty, despite robust Q2 S&P 500 earnings growth.

Analysis

US equity markets reversed early gains to close lower, reflecting a complex interplay between dovish monetary policy signals, escalating trade tensions, and significant company-specific news. The probability of a September Fed rate cut surged to 92%, driven by San Francisco Fed President Mary Daly's comments and weaker-than-expected labor data, where initial claims rose to 226,000 and continuing claims reached a 3.75-year high. However, this bullish macro signal was overshadowed by negative corporate developments and trade policy uncertainty. The Dow Jones was specifically pressured by Caterpillar's 3% decline after a Morgan Stanley downgrade citing tariff impacts, while Eli Lilly's stock plummeted over 14% on disappointing trial data for its weight-loss drug. President Trump's announcement of a 100% tariff on semiconductor imports, albeit with exemptions for US-based production, created a sharp divergence, boosting chipmakers like AMD (+5%) but adding to broader market anxiety. This environment of policy-driven volatility is occurring despite a robust Q2 earnings season, with S&P 500 profits on track to grow 9.1% y/y, far surpassing the 2.8% pre-season forecast, indicating a disconnect between strong underlying fundamentals and prevailing market sentiment.

Key Decisions for Investors

• Monitor incoming economic data closely, as the market has priced in a 92% chance of a September rate cut, making it highly sensitive to any figures that challenge the narrative of a softening labor market.
• Re-evaluate portfolio exposure to trade policy by considering longs in semiconductor firms with significant US production plans, such as AMD and NVDA, while reviewing downside risks for companies like Caterpillar and Elf Beauty that are more vulnerable to tariffs.
• Focus on companies providing robust forward guidance, as the severe punishment of firms like Fortinet (-25%) and Crocs (-25%) for weak outlooks suggests the market is prioritizing visibility over strong backward-looking results.
• Given Eli Lilly's -14% decline, investors in the pharmaceutical sector should reassess the competitive dynamics of the weight-loss drug market, as clinical trial outcomes are creating significant performance divergence against competitors like Novo Nordisk.